Abstract
Introduction
Staphylococcus aureus (S. aureus) is an important pathogen in both community-acquired and hospital-acquired pneumonia. S. aureus pneumonia has a high mortality rate and serious complications. Resistance to multiple antibiotics is a major challenge in the treatment of S. aureus pneumonia. Understanding the antibiotic resistance profile of S. aureus and the risk factors for mortality can help optimize antibiotic regimens and improve patient outcomes in S. aureus pneumonia.
Methods
A prospective cohort study of 118 patients diagnosed with S. aureus pneumonia between May 2021 and June 2023 was conducted, with a 30-day follow-up period. Demographic information, comorbidities, Charlson Comorbidity Index, clinical characteristics, outcomes, and complications were collected for each enrolled case. The data were processed and analyzed using R version 3.6.2.
Results
S. aureus pneumonia has a 30-day mortality rate of approximately 50%, with complication rates of 22% for acute respiratory distress syndrome (ARDS), 26.3% for septic shock, and 14.4% for acute kidney injury (AKI). Among patients with methicillin-resistant S. aureus (MRSA) pneumonia treated with vancomycin (n = 40), those with a vancomycin minimum inhibitory concentration (MIC) ≤ 1 had significantly higher cumulative survival at day 30 compared to those with MIC ≥ 2 (log-rank test p = 0.04). The prevalence of MRSA among S. aureus isolates was 84.7%. Hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) criteria for severe pneumonia were significantly associated with mortality in a multivariate Cox regression model based on the adaptive least absolute shrinkage and selection operator (LASSO).
Conclusions
S. aureus pneumonia is a severe clinical condition with high mortality and complication rates. MRSA has a high prevalence in Can Tho City, Vietnam. Hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting the IDSA/ATS criteria for severe pneumonia are risk factors for mortality in S. aureus pneumonia.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
Staphylococcus aureus (S. aureus) pneumonia exhibits a severe clinical course with complications and high mortality. Identifying mortality risk factors allows for early recognition and intervention, potentially improving outcomes. |
Beyond its virulence, S. aureus exhibits resistance to commonly used antibiotics in pneumonia treatment protocols. Evaluating the antibiotic resistance profile of S. aureus is essential for constructing evidence-based empirical treatment strategies. |
What was learned from this study? |
S. aureus pneumonia exhibits a substantial 30-day mortality rate of 43.8%. Mortality risk factors identified include hemoptysis, methicillin resistance (MRSA), acidosis (pH <7.35), and fulfillment of IDSA/ATS severe pneumonia criteria. |
The high MRSA prevalence (84.7%) among isolated S. aureus in this study suggests that conventional beta-lactam antibiotics may no longer be a reliable empirical therapy for clinically suspected S. aureus pneumonia. |
Introduction
Pneumonia is a significant global health concern, responsible for a substantial burden of morbidity and mortality worldwide [12]. Among the diverse pathogens contributing to this disease, Staphylococcus aureus (S. aureus) stands out as a formidable pathogen because of its potential to cause severe pneumonia and its resistance against commonly used antibiotics [3]. S. aureus is a significant etiological pathogen in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), accounting for approximately 2–16% of CAP cases and a notable proportion of HAP cases, ranging from 20% to 40% [11, 15, 21, 24, 32, 37, 42]. Pneumonia caused by S. aureus is associated with higher rates of morbidity and mortality compared to other bacterial etiologies, demanding urgent attention from healthcare providers and researchers. Prior investigations have revealed that S. aureus-associated mortality in nosocomial pneumonia is approximately 30–50% [2, 13, 44]. In contrast, CAP stemming from S. aureus is associated with mortality rates ranging from 20% to 50% [10, 13, 21, 39, 44], with potential escalation up to 56% in cases of necrotizing pneumonia linked to Panton-Valentine leukocidin (PVL)-producing S. aureus strains [20]. Compared to the causative pathogen Streptococcus pneumoniae, S. aureus pneumonia presents mortality rates three to four times higher [10]. This increased pathogenicity can be attributed to its high virulence factor and an array of antibiotic resistance mechanisms, resulting in formidable multidrug-resistant bacterial infections that significantly challenge treatment efforts [3].
Like many other regions, Can Tho City grapples with the challenges posed by pneumonia caused by this pathogen. A comprehensive understanding of the clinical manifestations, radiological findings, associated comorbidities, and clinical outcomes is indispensable in enhancing the diagnostic accuracy and management of S. aureus pneumonia. Furthermore, a thorough evaluation of antimicrobial susceptibility profiles in local S. aureus isolates is imperative to guide the development of evidence-based empirical antibiotic protocols. In the context of Vietnam, the impact of S. aureus pneumonia represents a pressing public health issue. Diverse factors, including geographical climate, socio-economic conditions, population density, and healthcare infrastructure, may influence this infection’s clinical presentation and outcomes in the region. Our investigation aims to delineate the clinical and laboratory features, encompassing information on antimicrobial resistance, clinical endpoints, and predictors associated with 30-day mortality in S. aureus pneumonia.
Methods
Study Design and Population
This prospective cohort study was conducted at two hospitals in Can Tho City, Can Tho Central General Hospital and Can Tho University of Medicine and Pharmacy Hospital, between May 2021 and June 2023.
We included patients aged 18 years or older diagnosed with S. aureus pneumonia on the basis of the Centers for Disease Control and Prevention (CDC) 2021 criteria for common bacterial pneumonia [6]. Exclusion criteria included active lung disease, acute hemodynamic pulmonary edema, or concurrent co-infection of S. aureus with other bacterial pathogens.
After informed consent was obtained, baseline data were collected and participants were followed up until 30 days or death, whichever happened first. Antibiotic treatment was administered in accordance with the established hospital protocols. This study was ethically approved by the Institutional Review Board of Can Tho University of Medicine and Pharmacy (approval number 1388/QD-DHYDCT in June 2021).
Definition of Staphylococcus aureus Pneumonia
According to the 2021 CDC criteria for common bacterial pneumonia, S. aureus pneumonia is diagnosed if the patient meets the following criteria: (1) presence of infiltrative lesions and/or progressive changes evident on chest X-ray, (2) fulfillment of at least one criterion from the following: fever above 38 °C, leukopenia (leukocyte count < 4000/mm3), leukocytosis (leukocyte count > 12,000/mm3), or altered mental status in adults aged 70 years or older with no other identifiable cause, coupled with at least one criterion from the following: new onset or worsening cough, dyspnea, tachypnea, rales or bronchial breath sounds, or deteriorating gas exchange, and (3) identification of S. aureus isolates from blood, pleural fluid, and/or lower respiratory tract specimen [6]. For lower respiratory tract secretions, to ensure that the samples were collected at the lower respiratory tract, prior to processing, they underwent a rigorous quality check by Gram-staining and quantifying the squamous epithelial cells and polymorphonuclear cells observed in the smear. A sputum specimen was deemed high quality if it exhibited fewer than 10 squamous epithelial cells and more than 25 polymorphonuclear cells per low-power field (magnification ×100). S. aureus is identified as the causative pathogen when the bacterial count in the culture exceeds the microbiological diagnostic thresholds: 103 CFU/mL for protected bronchial brush samples, 104 CFU/mL for bronchoalveolar lavage specimens, and 105 CFU/mL for both sputum and tracheobronchial aspirates.
Definition of Variables
Pneumonia was classified into (1) community-acquired pneumonia (CAP), which denotes pneumonia developing outside of hospital or healthcare facilities; (2) hospital-acquired pneumonia (HAP), characterized by pneumonia that arises after 48 h of hospital admission; and (3) ventilator-associated pneumonia (VAP), referring to pneumonia occurring 48–72 h after endotracheal intubation [6, 26, 34]. The definition of appropriate empirical therapy consisted of the administration of at least one antibiotic agent demonstrating in vitro susceptibility against the identified pathogen within 24 h of pneumonia diagnosis, preceding the availability of antimicrobial susceptibility testing results. Failure of empiric antibiotic therapy was defined as mortality during the initial treatment phase or the need to switch from the initial agents to alternative antibiotics within 48–72 h owing to clinical instability. The Charlson Comorbidity Index (CCI) is a scoring system assessing the impact of concurrent comorbidities on long-term survival rates, with CCI > 3 considered to be associated with an increased risk of mortality and treatment failure [5, 8]. Acute respiratory distress syndrome (ARDS) is diagnosed according to the Berlin 2012 criteria for definition of ARDS [17]. The diagnosis of septic shock was made in accordance with The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [41].
Outcomes
The primary outcome was mortality during the follow-up period. Secondary outcomes were appropriate empiric antibiotic regimens, failure of empiric antibiotic regimens, ARDS, septic shock, intensive care unit admission and associated mortality, the need for mechanical ventilation, ICU stay duration, and hospital stay.
Data Collection
We collected demographic information, comorbidities, and physiologic parameters on admission. The assessed comorbidities included cancer, central nervous system (CNS) disease, chronic obstructive pulmonary disease (COPD), heart failure, coronary artery disease, kidney failure, diabetes, liver disease, kidney failure, blood disorders, and heart arrhythmia, according to the CCI. During hospitalization, we daily documented clinical manifestations, including cough, dyspnea, hemoptysis, and purulent sputum. Additionally, we collected the antibiotic resistance profiles of S. aureus through an antibiogram. The Vitek2® system (BioMerieux Inc. Marcy l’Etoile, Lyon, France) was used to measure minimum inhibitory concentrations (MICs) of antimicrobials. For patients who were discharged alive, we asked them to return for follow-up or called them via telephone on day 30, after the diagnosis of S. aureus pneumonia was established to assess the primary outcome.
Statistical Analysis
Continuous variables with non-normal distributions were summarized as medians with corresponding interquartile ranges (IQRs). Group comparisons of categorical variables were performed using the chi-square test or Fisher’s exact test, as determined by the appropriateness of each test. Continuous variables were compared using Student’s t test or the Mann–Whitney U test, depending on the normality of their distribution. The least absolute shrinkage and selection operator (LASSO) method was combined with Cox proportional hazards regression to identify independent factors associated with 30-day mortality. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) and P values were derived from multivariate models. An odds ratio (OR) > 1 denotes an increased risk of the outcome. All statistical tests were two-sided, and a P value less than 0.05 was deemed statistically significant. Data analysis was performed using R version 3.6.2 (The R Foundation).
Results
Baseline Characteristic of Study Patients
Between May 2021 and June 2023, a total of 118 eligible patients were recruited to the study (Fig. 1), among which 76 (64.4%) had CAP, 31 (26.3%) HAP, and 11 (9.3%) VAP.
More than 60% of patients were ≥ 60 years of age. The most common comorbidities included diabetes mellitus (30.5%), CNS disease (28.8%), and coronary artery disease and heart failure (18.6%).
Fifty-seven (48.3%) patients died on day 30. Comparing survivors and non-survivors at day 30, no statistically significant differences were observed in terms of age, gender, pneumonia classifications, underlying medical conditions, and lung imaging abnormalities (Table 1). However, non-survivors had a significantly higher percentage of severe dyspnea (84.2% vs. 63.9%, p = 0.012), hemoptysis (17.5% vs. 3.3%, p = 0.01), respiratory distress (PaO2 < 60 mmHg or SpO2 < 90% or oxygen therapy requirement) (96.5% vs. 68.9%, p < 0.001), PaO2/FiO2 ≤ 250 (73.7% vs. 32.8%, p < 0.001), pH < 7.35 (26.3% vs. 3.3%), and platelet count < 100,000/mm3 (14% vs. 1.6%, p = 0.011). Non-survivors also had more severe pneumonia manifestations according to the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) criteria (75.4% vs. 23%, p < 0.001).
Microbiological Findings and Antibiotic Resistance
Among the isolated strains of S. aureus, 84.7% were methicillin-resistant Staphylococcus aureus (MRSA). The proportion of MRSA increased from CAP and HAP to VAP (83.1%, 86.7%, and 90.9%, respectively, p = 0.753). Non-survivors had a statistically significant higher percentage of resistance to oxacillin, levofloxacin, and gentamicin (Table 2).
Clinical Outcomes and Complications
Non-survivors had higher incidence of severe complications including ARDS (42.1% vs. 3.3%, p < 0.001), septic shock (47.4% vs. 6.6%, p < 0.001), and AKI (21.1% vs. 8.2%, p = 0.047) and a shorter median length of hospital stay (8 vs. 15 days, p < 0.001). Patients who responded to empiric antibiotic therapy also had longer hospital stay compared to those who did not respond (median (Q1–Q3) 13 (8–20.5) vs. 10 (5–18) days, p < 0.028).
Among patients with MRSA pneumonia treated with vancomycin (n = 40), patients with a vancomycin MIC ≤ 1 had a significantly higher cumulative survival at day 30 compared to patients with MIC ≥ 2 (log-rank test p = 0.04) Fig. 2.
Risk Factors for 30-Day Mortality
Shortness of breath, PaO2 < 60 mmHg or SpO2 < 90% or oxygen therapy requirement, PaO2/ FiO2 ≤ 250, hemoptysis, acidosis (pH < 7.35), WBC < 4000/mm3, platelet count < 100,000/mm3, methicillin resistance, and meeting IDSA/ATS criteria for severe pneumonia were included in the final multivariable Cox proportional hazards model after selection using LASSO. The multivariate Cox regression model based on the adaptive LASSO demonstrated that hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting IDSA/ATS criteria for severe pneumonia were significantly associated with mortality in patients with S. aureus pneumonia (Table 3).
Discussion
In this study, we investigated the mortality and associated factors in patients with S. aureus pneumonia. We found that these patients had a high mortality rate and severe complications such as ARDS, septic shock, and AKI. We also identified several important risk factors for mortality, including hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting the IDSA/ATS criteria for severe pneumonia. Additionally, this study demonstrated a dramatic increase in the prevalence of MRSA in Can Tho City, Vietnam.
The 30-day mortality in our patients was nearly 50% and was not associated with pneumonia classification (CAP, HAP, and VAP). Our findings were consistent with previous reports [13, 44]. HAP and VAP caused by S. aureus are often associated with high mortality rates, ranging from 30% to 50% [2, 13, 44]. This is because these infections typically occur in elderly patients with multiple comorbidities, as well as the increasing prevalence of multidrug-resistant S. aureus strains in healthcare settings [51]. CAP caused by S. aureus is often a secondary infection following influenza in young, healthy patients. Despite this, the mortality rate of CAP caused by S. aureus is still high, ranging from 20% to 50% [10, 13, 21, 39, 44]. This is because these infections are often associated with high-virulence strains of S. aureus that produce the PVL toxin [23, 43, 50, 51]. We also found that patients who died had a significantly higher incidence of ARDS, septic shock, and AKI. In a study by Gillet et al., refractory shock and respiratory failure requiring mechanical ventilation were the sole causes of mortality in patients with S. aureus pneumonia [20]. These severe complications are associated with several toxins produced by S. aureus, with PVL and toxic shock syndrome toxin-1 (TSST-1) playing a major role in the pathogenesis of these complications [1, 20, 23, 50]. Toxin suppression therapies, such as neutralizing antibodies or protein synthesis inhibitors such as linezolid, clindamycin, and rifampicin, have been shown to improve outcomes in patients with S. aureus pneumonia caused by PVL- and TSST-1-producing strains [1, 23, 35, 40, 49].
The prevalence of MRSA in this study (84.7%) was markedly higher than the regional and global averages (14–60%) [10, 39, 45, 46, 52]. A recent study conducted in Vietnam by Tran et al. on children with CAP caused by S. aureus found that 74% of the isolates were MRSA [47]. The higher prevalence of MRSA in our study may be due to the older age of our study participants, the presence of comorbidities, a higher risk of prior antibiotic exposure, and the fact that our study did not exclude HAP cases. These findings indicate a concerningly rapid increase in MRSA prevalence in Vietnam compared to the global average. Remarkably, we found no significant differences in MRSA prevalence across pneumonia categories based on infection source, contrary to earlier seminal studies that asserted higher MRSA rates in HAP compared to community-acquired cases [25, 44]. These findings underscore the concerning reality of the increasing prevalence of MRSA in the community in Vietnam. The higher MRSA prevalence also suggests that conventional beta-lactam antibiotics may no longer be a reliable empirical therapy for clinically suspected S. aureus pneumonia.
Among patients treated with vancomycin for MRSA, higher vancomycin MIC (≥ 2 µg/mL) was associated with increased mortality. Studies on the association of vancomycin MIC and treatment outcomes among patients with MRSA pneumonia have not shown consistent results regarding the impact of vancomycin MIC on clinical outcomes [9, 22, 33, 36, 44, 48]. The heterogeneity in the results of these studies may be attributed to differences in the study population, pneumonia classification, vancomycin dosing, the use of therapeutic drug monitoring, and the methods used to determine and interpret vancomycin MIC. Our findings underscore the need for cautious vancomycin administration in patients with MRSA pneumonia caused by isolates with an MIC ≥ 2 µg/mL, and alternative antibiotic therapies should be considered.
We found that the risk factors for mortality in patients with S. aureus pneumonia included hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting the IDSA/ATS criteria for severe pneumonia. Hemoptysis is one of the independent prognostic factors for mortality in S. aureus pneumonia, as documented in prior studies [4, 18, 20, 27, 30, 40]. This manifestation is associated with necrotizing pneumonia, which is observed in infections by certain strains of S. aureus capable of producing PVL toxins. This toxin constitutes a significant virulence factor that exacerbates the severity and mortality of S. aureus pneumonia, as reported in several previous studies [4, 18, 20, 29, 31, 40]. Methicillin resistance in S. aureus pneumonia confers resistance to common beta-lactam antibiotics, leading to increased therapeutic failure, prolonged hospital stay, and increased treatment costs [19, 38, 52]. However, Sicot et al. suggest that methicillin resistance does not adversely impact the outcomes of S. aureus pneumonia [40]. In their study, Sicot et al. investigated CAP caused by PVL-producing S. aureus and found that patients exhibited high mortality despite appropriate antibiotic therapy. This is attributed to the upregulation of PVL toxin production by S. aureus in response to beta-lactam antibiotics, which are commonly prescribed for methicillin-sensitive S. aureus pneumonia, thereby enhancing the virulence of S. aureus [53, 54]. Arterial pH < 7.35 is a criterion contributing to the assessment of severity and 30-day mortality in CAP according to the Pneumonia Patient Outcomes Research Team (PORT) score [16]. Arterial pH is also a criterion in the severity assessment of CAP, such as SCAP and SMART-COP [7, 14]. Once again, our research underscores the significance of this risk factor in predicting 30-day mortality, particularly in S. aureus pneumonia. The IDSA/ATS criteria for pneumonia severity are recommended for assessing the need for ICU admission and 30-day mortality in pneumonia [28, 55]. These criteria exhibit higher specificity than CURB-65 and greater sensitivity than PSI, demonstrating efficacy in predicting outcomes for Streptococcus pneumoniae pneumonia [28, 55]. Our study provides evidence of risk factors predicting mortality in patients with S. aureus pneumonia. When clinical scenarios of pneumonia strongly suggest S. aureus as the likely causative bacterium, with Gram stain results suggestive of S. aureus or confirmed by microbiological testing, clinicians should be attentive to these risks to detect cases prone to adverse outcomes early and implement appropriate therapeutic interventions.
The strengths of the study include a prospective study design with a data collection period of approximately 2 years, conducted at two major hospitals in Can Tho City, Vietnam. However, the study has several limitations, including a relatively short follow-up period, lack of assessment of recurrent pneumonia cases and subsequent outcomes, limited precision in MIC measurement, and absence of a unified scoring system to assess overall pneumonia severity.
Conclusion
S. aureus pneumonia manifests as a severe clinical condition with high mortality and morbidity rates. MRSA has a high prevalence in Can Tho City, suggesting that beta-lactam antibiotics may not be appropriate for empirical antibiotic therapy in suspected S. aureus pneumonia. Hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting the IDSA/ATS criteria for severe pneumonia are risk factors for mortality in S. aureus pneumonia. These risk factors can help clinicians identify patients at risk for severe disease progression and then implement timely medical interventions to improve patient outcomes.
Data Availability
The data underlying this study are available from the corresponding author upon legitimate request.
References
Ahmad-Mansour N, Loubet P, Pouget C, et al. Staphylococcus aureus toxins: an update on their pathogenic properties and potential treatments. Toxins (Basel). 2021;13(10):677.
Althaqafi AO, Matar MJ, Moghnieh R, et al. Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia. Infect Drug Resist. 2017;10:49–55.
Benhamou D, Carrie AS, Lecomte F. Staphylococcus aureus: role and impact in the treatment of nosocomial pneumonia. Rev Mal Respir. 2005;22(4):595–603.
Boussaud V, Parrot A, Mayaud C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med. 2003;29(10):1840–3.
Cacciatore F, Gaudiosi C, Mazzella F, et al. Pneumonia and hospitalizations in the elderly. Geriatr Care. 2017. https://doi.org/10.4081/gc.2017.6377.
CDC. 2021. Pneumonia (Ventilator-associated pneumonia (VAP) and non-ventilator-associated pneumonia (PNEU)) Event, Device-associated Module. https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf. Accessed 2 Mar 2021.
Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375–84.
Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–40.
Choi EY, Huh JW, Lim CM, et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med. 2011;37(4):639–47.
Cilloniz C, Dominedo C, Gabarrus A, et al. Methicillin-susceptible Staphylococcus aureus in community-acquired pneumonia: risk factors and outcomes. J Infect. 2021;82(1):76–83.
Cilloniz C, Ewig S, Gabarrus A, et al. Seasonality of pathogens causing community-acquired pneumonia. Respirology. 2017;22(4):778–85.
Collaborators GL. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133–61.
De la Calle C, Morata L, Cobos-Trigueros N, et al. Staphylococcus aureus bacteremic pneumonia. Eur J Clin Microbiol Infect Dis. 2016;35(3):497–502.
Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174(11):1249–56.
File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii19-32.
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–50.
Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.
Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753–9.
Gillet Y, Tristan A, Rasigade JP, et al. Prognostic factors of severe community-acquired staphylococcal pneumonia in France. Eur Respir J. 2021;58(5):2004445.
Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45(3):315–21.
Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis. 2006;12(6):894–9.
Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest. 2010;138(6):1356–62.
He H, Wunderink RG. Staphylococcus aureus pneumonia in the community. Semin Respir Crit Care Med. 2020;41(4):470–9.
Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–27.
Jung WJ, Kang YA, Park MS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis. 2013;13:370.
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.
Khanafer N, Sicot N, Vanhems P, et al. Severe leukopenia in Staphylococcus aureus-necrotizing, community-acquired pneumonia: risk factors and impact on survival. BMC Infect Dis. 2013;13:359.
Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med. 2009;27(8):968–74.
Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315(5815):1130–3.
Li HT, Zhang TT, Huang J, et al. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration. 2011;81(6):448–60.
Loffler B, Niemann S, Ehrhardt C, et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther. 2013;11(10):1041–51.
Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii33-44.
Machado DP, Goldani LZ, Paiva RM, et al. The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia. Can J Infect Dis Med Microbiol. 2013;24(3):e75–9.
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.
Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):S378–85.
Ruiz-Ramos J, Vidal-Cortes P, Diaz-Lamas A, et al. Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter? Eur J Clin Microbiol Infect Dis. 2017;36(9):1569–75.
Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis. 2016;63(3):300–9.
Shorr AFCA, Kollef MH, Chastre J, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10(3):R97.
Shorr AF, Haque N, Taneja C, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48(9):3258–62.
Sicot N, Khanafer N, Meyssonnier V, et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia–results of a prospective observational study. Clin Microbiol Infect. 2013;19(3):E142–8.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.
Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–27.
Tacconelli E, De Angelis G. Pneumonia due to methicillin-resistant Staphylococcus aureus: clinical features, diagnosis and management. Curr Opin Pulm Med. 2009;15(3):218–22.
Tadros M, Williams V, Coleman BL, et al. Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS ONE. 2013;8(9): e75171.
Thabet N, Shindo Y, Okumura J, et al. Clinical characteristics and risk factors for mortality in patients with community-acquired staphylococcal pneumonia. Nagoya J Med Sci. 2022;84(2):247–59.
Tilouche L, Ben DR, Boughattas S, et al. Staphylococcus aureus ventilator-associated pneumonia: a study of bacterio-epidemiological profile and virulence factors. Curr Microbiol. 2021;78(7):2556–62.
Tran KQ, Nguyen TTD, Pham VH, et al. Pathogenic role and antibiotic resistance of methicillin-resistant Staphylococcus aureus (MRSA) strains causing severe community-acquired pneumonia in Vietnamese children. Adv Respir Med. 2023;91(2):135–45.
van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.
Vestergaard M, Frees D, Ingmer H. Antibiotic resistance and the MRSA problem. Microbiol Spectr. 2019. https://doi.org/10.1128/microbiolspec.GPP3-0057-2018.
Vlaeminck J, Raafat D, Surmann K, et al. Exploring virulence factors and alternative therapies against Staphylococcus aureus pneumonia. Toxins (Basel). 2020;12(11):721.
Woods C, Colice G. Methicillin-resistant Staphylococcus aureus pneumonia in adults. Expert Rev Respir Med. 2014;8(5):641–51.
Zhang QR, Chen H, Liu B, et al. Methicillin-resistant Staphylococcus aureus pneumonia in diabetics: a single-center, retrospective analysis. Chin Med J (Engl). 2019;132(12):1429–34.
Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on panton-valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect. 2008;14(4):384–8.
Dumitrescu O, Boisset S, Badiou C, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007;51(4):1515–9.
Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141.
Acknowledgements
We would like to express our sincere gratitude to Can Tho University of Medicine and Pharmacy, Can Tho University of Medicine and Pharmacy Hospital and Can Tho Central General Hospital for their invaluable support and provision of essential resources that made this study possible. We would like to thank all the participants of the study.
Medical Writing, Editorial, and Other Assistance.
We are grateful to Dr. Long Hoang-Bao for his helpful editorial assistance in the preparation of this article.
Authorship.
All authors meet the ICMJE criteria for authorship and are accountable for the overall integrity of the work.
Funding
No funding or sponsorship was received for this study or publication of this article.
Author information
Authors and Affiliations
Contributions
Conceptualized. All authors conceptualized and designed the study. Thu Vo-Pham-Minh, Thien Dinh-Chi, Tran Nguyen-Thi-Hong, Thuy Cao-Thi-My prepared the materials, collected the data, and analyzed it. Thu Vo-Pham-Minh, Dang Tran-Cong, Thien Dinh-Chi, and Hung Phan-Viet drafted the manuscript, and all authors commented on it. All authors read and approved the final manuscript. Sy Duong-Quy is the corresponding author.
Corresponding author
Ethics declarations
Conflict of Interest
Thu Vo-Pham-Minh, Dang Tran-Cong, Thien Dinh-Chi; Hung Phan-Viet; Tran Nguyen-Thi-Hong; Thuy Cao-Thi-My; Hien Nguyen-Thi-Dieu; Vu Nguyen-Thien, and Duong Vo-Thai, Sy Duong-Quy declared that they have no conflict of interests. Sy Duong-Quy is an Editorial Board member of Pulmonary Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
Ethical Approval
All procedures performed in this study were approved by the Institutional Review Board of Can Tho University of Medicine and Pharmacy (IRB approval number 1388/QD-DHYDCT, June 2021) and were conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Participants were informed of the study’s purpose and their right to withdraw at any time. There are no interventions were performed on the participants in this observational study.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Vo-Pham-Minh, T., Tran-Cong, D., Phan-Viet, H. et al. Staphylococcus aureus Pneumonia in Can Tho, Vietnam: Clinical Characteristics, Antimicrobial Resistance Profile and Risk Factors of Mortality. Pulm Ther (2024). https://doi.org/10.1007/s41030-024-00254-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s41030-024-00254-2